HOME > About Company > Sumagen at glance
 

Sumagen Co., Ltd. is a biotechnology company and a member of Curo Group. Sumagen holds Exclusive License for Dr. Kang, Chil-yong’s HIV/AIDS vaccine development and its commercialization. Sumagen is also holder of a Preferred Bidding Rights for the development and subsequent production and marketing for HCV (Hepatitis C Virus) vaccine and the next generation antibiotics of Dr. Heinrich.


Sumagen’s HIV/AIDS vaccine was approved by USFDA for its IND in December of 2011, which now is on the Phase I human clinical trials in the United States, conducted by world renowned with USFDA’s approval for Clinical Trials on Humans, Sumagen is now in Phase I Clinical Trials, conducted by PPD in the United States. Sumagen’s HIV/AIDS vaccine is also supported for its R&D cost from the HIV/AIDS vaccine development fund, jointly launched by the Bill and Melinda Gates Foundation and the government of Canada.

 

Company Name

Sumagen Co., Ltd.

CEO and Representative Director

Mr. Cho, Jung-gee

Principle Researcher

Dr. Kang, Chil-yong (Professor, Microbiology and Immunology at UWO, Canada)

Development Manager

Dr. Lee, Sang-kyun (former president of Toxicology Center of LG Life Science)

Capital Stock

4.3 Billion Korean Won (appx. 4 Million US Dollar)

Establishment

September 20, 2000

Location

Head office: Dongwon B/D 4F, Teheran-ro 77-7 Gangnam-gu, Seoul, Korea
Canada: 700 Collip circle, suite 118, London, ON N6G4X8, CANADA

Number of Employee

13 (6 in R&D)

Tel.

+82-2-2141-2800 (Fax.+82-2-2141-2810)